181 related articles for article (PubMed ID: 31756944)
1. FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.
Watanabe D; Nogami A; Okada K; Akiyama H; Umezawa Y; Miura O
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756944
[TBL] [Abstract][Full Text] [Related]
2. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway.
Nogami A; Okada K; Ishida S; Akiyama H; Umezawa Y; Miura O
Transl Oncol; 2019 Feb; 12(2):336-349. PubMed ID: 30472492
[TBL] [Abstract][Full Text] [Related]
4. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
5. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
[TBL] [Abstract][Full Text] [Related]
6. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
8. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
9. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
10. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Scarpa M; Singh P; Bailey CM; Lee JK; Kapoor S; Lapidus RG; Niyongere S; Sangodkar J; Wang Y; Perrotti D; Narla G; Baer MR
Mol Cancer Ther; 2021 Apr; 20(4):676-690. PubMed ID: 33568357
[No Abstract] [Full Text] [Related]
11. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
Green AS; Maciel TT; Hospital MA; Yin C; Mazed F; Townsend EC; Pilorge S; Lambert M; Paubelle E; Jacquel A; Zylbersztejn F; Decroocq J; Poulain L; Sujobert P; Jacque N; Adam K; So JC; Kosmider O; Auberger P; Hermine O; Weinstock DM; Lacombe C; Mayeux P; Vanasse GJ; Leung AY; Moura IC; Bouscary D; Tamburini J
Sci Adv; 2015 Sep; 1(8):e1500221. PubMed ID: 26601252
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
Takami M; Katayama K; Noguchi K; Sugimoto Y
Biochem Biophys Res Commun; 2018 Sep; 503(3):1364-1371. PubMed ID: 30017192
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
14. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.
Minami Y; Yamamoto K; Kiyoi H; Ueda R; Saito H; Naoe T
Blood; 2003 Oct; 102(8):2969-75. PubMed ID: 12842996
[TBL] [Abstract][Full Text] [Related]
15. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
16. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.
Czardybon W; Windak R; Gołas A; Gałęzowski M; Sabiniarz A; Dolata I; Salwińska M; Guzik P; Zawadzka M; Gabor-Worwa E; Winnik B; Żurawska M; Kolasińska E; Wincza E; Bugaj M; Danielewicz M; Majewska E; Mazan M; Dubin G; Noyszewska-Kania M; Jabłońska E; Szydłowski M; Sewastianik T; Puła B; Szumera-Ciećkiewicz A; Prochorec-Sobieszek M; Mądro E; Lech-Marańda E; Warzocha K; Tamburini J; Juszczyński P; Brzózka K
Oncotarget; 2018 Mar; 9(24):16917-16931. PubMed ID: 29682194
[TBL] [Abstract][Full Text] [Related]
17. Cytarabine-Resistant
Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
[TBL] [Abstract][Full Text] [Related]
18. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Zhou F; Ge Z; Chen B
Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
[TBL] [Abstract][Full Text] [Related]
19. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
[TBL] [Abstract][Full Text] [Related]
20. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]